A consortium of hospital systems and three foundations is moving ahead with a nonprofit drugmaker that would produce some of the generic medicines health care facilities need the most.
In signs the health care market may be maturing, an analysis of insurance filings shows premiums will rise less than 4 percent on average and companies plan to market more policies in more places.
A survey by the research group NORC at the University of Chicago shows 57 percent of American adults have been surprised by a health care bill that their insurance didn’t pay for.
CVS Caremark is suing Ohio Medicaid officials to block release of a report the agency commissioned to show how the pharmacy benefit manager does business, and ultimately how drug prices are set.
Companies that negotiate drug prices for insurance plans keep a big cut of the money. In Ohio, a battle is brewing over whether their services are worth the cost.
A new Trump administration rule allows consumers to buy health care plans that are exempt from certain Affordable Care Act rules — and therefore cheaper.
The Trump administration on Wednesday releases its final rule on short-term health policies that don’t have the same consumer protections as plans governed by the Affordable Care Act.
Louisiana and Gilead Sciences are working on a deal that would change how the state pays for expensive hepatitis C drugs, with the goal of eliminating the disease in that state.
NPR’s Alison Kodjak and The Center for Public Integrity have been looking at all the ways the drug industry tries to keep Medicaid money flowing. Here they examine how the drug industry’s massive lobbying effort in every state has blocked efforts to co…